SEC Form 4 · accession 0001193125-26-361096
4D Molecular Therapeutics, Inc. · FDMT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Kirn
Officer — See Remarks · Director
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 4:06 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001650648
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 19, 2026 | M | 50,000 | $4.14 | A | 894,895 | D | |
| Common StockF2 | Aug 19, 2026 | S | 43,149 | $15.3566 | D | 851,746 | D | |
| Common StockF3 | Aug 19, 2026 | S | 25,927 | $16.4173 | D | 825,819 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $4.14 | Aug 19, 2026 | M | 50,000 | D | — | Mar 5, 2035 | Common Stock | 50,000 | 217,500 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 9, 2026.
- F2The transaction was executed in multiple trades in prices ranging from $14.91 to $15.84, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3The transaction was executed in multiple trades in prices ranging from $15.97 to $16.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Remarks
President and Chief Executive Officer